Khan Siddiqui - Oct 31, 2022 Form 4 Insider Report for Hyperfine, Inc. (HYPR)

Role
CMO and Chief Strategy Officer
Signature
/s/ Neela Paykel, Attorney-in-Fact
Stock symbol
HYPR
Transactions as of
Oct 31, 2022
Transactions value $
$0
Form type
4
Date filed
11/1/2022, 05:57 PM
Previous filing
Aug 16, 2022
Next filing
Nov 16, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HYPR Stock Option (right to buy) Disposed to Issuer -235K -100% 0 Oct 31, 2022 Class A Common Stock 235K $3.76 Direct F1
transaction HYPR Stock Option (right to buy) Award +235K 235K Oct 31, 2022 Class A Common Stock 235K $0.91 Direct F1
transaction HYPR Stock Option (right to buy) Disposed to Issuer -54K -100% 0 Oct 31, 2022 Class A Common Stock 54K $3.27 Direct F2
transaction HYPR Stock Option (right to buy) Award +54K 54K Oct 31, 2022 Class A Common Stock 54K $0.91 Direct F2
transaction HYPR Stock Option (right to buy) Disposed to Issuer -1.8K -100% 0 Oct 31, 2022 Class A Common Stock 1.8K $5.24 Direct F3
transaction HYPR Stock Option (right to buy) Award +1.8K 1.8K Oct 31, 2022 Class A Common Stock 1.8K $0.91 Direct F3
transaction HYPR Stock Option (right to buy) Disposed to Issuer -110K -100% 0 Oct 31, 2022 Class A Common Stock 110K $3.90 Direct F4
transaction HYPR Stock Option (right to buy) Award +110K 110K Oct 31, 2022 Class A Common Stock 110K $0.91 Direct F4
transaction HYPR Stock Option (right to buy) Disposed to Issuer -74K -100% 0 Oct 31, 2022 Class A Common Stock 74K $3.90 Direct F5
transaction HYPR Stock Option (right to buy) Award +74K 74K Oct 31, 2022 Class A Common Stock 74K $0.91 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 161,657 shares vested and the remainder of the options vesting in equal monthly installments, subject to Mr. Siddiqui's continued service on each vesting date.
F2 The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of which 23,646 shares vested and the remainder of the options vesting in equal monthly installments, subject to Mr. Siddiqui's continued service on each vesting date.
F3 The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on December 22, 2021, of whlich 636 shares vested and the remainder of the options vesting in equal monthly installments, subject to Mr. Siddiqui's continued service on each vesting date.
F4 The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on February 9, 2022, of which 45,833 shares vested and the remainder of the options vesting in equal monthly installments, subject to Mr. Siddiqui's continued service on each vesting date.
F5 The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Dr. Siddiqui's continued service through the applicable vesting date.